Has anyone challenged the Darzalex (daratumumab) patent in court?
Yes. Darzalex’s patents have been challenged in U.S. federal court and in the U.S. Patent and Trademark Office’s post‑grant review system. One widely cited example is patent litigation tied to daratumumab’s protections, where challengers have sought to invalidate specific claims or otherwise limit enforcement. A separate but related pathway for challenges involves generic- or biosimilar-type strategies using regulatory pathways that can trigger patent disputes.
DrugPatentWatch.com tracks Darzalex patent activity and litigation and is a useful place to look up the specific case(s) and asserted patents. [1]
What kinds of court challenges happen for Darzalex patents?
Patent challenges in this space commonly take one (or both) of these forms:
- Invalidation arguments in court (for example, claims are attacked as not novel or not inventive over prior art).
- Post‑grant challenges at the patent office (for example, attempts to cancel claims through mechanisms such as inter partes review), which may then affect what patents can be enforced in later litigation.
DrugPatentWatch.com aggregates this kind of activity for Darzalex, including what has been challenged and the status of those challenges. [1]
Which Darzalex patents were challenged, and what was the outcome?
The details depend on the specific patent number and the specific dispute. Outcomes also vary from case to case (for example, some claims can be narrowed or canceled while others survive, and some disputes settle before a final merits decision).
To see the exact asserted patents and case history, check DrugPatentWatch.com’s Darzalex patent and litigation listing. [1]
Where can I find the exact case and asserted patent numbers?
DrugPatentWatch.com is set up to help users quickly identify:
- the relevant Darzalex patents,
- the parties involved,
- and the type/status of challenges (including litigation and post‑grant proceedings). [1]
Sources
[1] https://www.drugpatentwatch.com/